Idrees Abbas / SOPA Images / LightRocket / Getty Images Shares of SpringWorks Therapeutics soared on Monday following a report that German medical firm Merck KGaA could acquire the company.
On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...
Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...
SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...
5d
Stocktwits on MSNSpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...
Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX ... that approval was likely one of the conditions for Merck KGaA (MKGAY) to make an “official” offer and expects ...
Merck KGaA reaffirmed its strong performance ... but provided little additional information on ongoing acquisition talks with SpringWorks Therapeutics. Speculation surrounding a potential ...
A potential acquisition of SpringWorks Therapeutics by Merck KGaA could bring significant benefits to both companies and potentially create substantial value for shareholders: 1. Enhanced resources: ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 13,068 call options on the stock. This is an increase of 223% compared to ...
SpringWorks Therapeutics Inc . (NASDAQ ... most significant developments for SpringWorks is the ongoing merger and acquisition discussions with Merck KGaA. Analysts view this potential acquisition as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results